Li et al. concluded that hBMSC-EVs promoted OA-chondrocyte (OA-CH) proliferation and migration and reduced apoptosis via downregulation of MMP13, ALPL, IL-1β-activated pro-inflammatory Erk1/2, PI3K/Akt, p38, TAK1, and NF-κB signaling pathways and increased gene expression of PRG4, BCL2, and ACAN (aggrecan) [86]. The gene discussed is ACAN; the disease is cyclic hematopoiesis.